GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (STU:GE91) » Definitions » Cyclically Adjusted FCF per Share

Genmab A/S (STU:GE91) Cyclically Adjusted FCF per Share : €0.53 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Genmab A/S's adjusted free cash flow per share for the three months ended in Mar. 2024 was €0.303. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.53 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Genmab A/S's average Cyclically Adjusted FCF Growth Rate was 28.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 37.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 72.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Genmab A/S was 115.80% per year. The lowest was 37.30% per year. And the median was 86.50% per year.

As of today (2024-05-27), Genmab A/S's current stock price is €27.00. Genmab A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.53. Genmab A/S's Cyclically Adjusted Price-to-FCF of today is 50.94.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genmab A/S was 914.08. The lowest was 48.40. And the median was 158.63.


Genmab A/S Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted FCF per Share Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.19 0.25 0.35 0.49

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.42 0.46 0.49 0.53

Competitive Comparison of Genmab A/S's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted Price-to-FCF falls into.



Genmab A/S Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.303/118.4000*118.4000
=0.303

Current CPI (Mar. 2024) = 118.4000.

Genmab A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.011 99.700 0.013
201409 0.006 99.700 0.007
201412 0.001 99.400 0.001
201503 -0.017 100.200 -0.020
201506 -0.026 100.300 -0.031
201509 0.030 100.200 0.035
201512 0.053 99.800 0.063
201603 -0.003 100.200 -0.004
201606 0.045 100.600 0.053
201609 0.044 100.200 0.052
201612 -0.022 100.300 -0.026
201703 0.162 101.200 0.190
201706 0.110 101.200 0.129
201709 0.003 101.800 0.003
201712 0.049 101.300 0.057
201803 0.094 101.700 0.109
201806 0.025 102.300 0.029
201809 -0.043 102.400 -0.050
201812 0.039 102.100 0.045
201903 0.136 102.900 0.156
201906 0.036 102.900 0.041
201909 0.056 102.900 0.064
201912 0.030 102.900 0.035
202003 0.378 103.300 0.433
202006 0.019 103.200 0.022
202009 1.026 103.500 1.174
202012 -0.174 103.400 -0.199
202103 0.236 104.300 0.268
202106 0.056 105.000 0.063
202109 0.075 105.800 0.084
202112 0.035 106.600 0.039
202203 0.108 109.900 0.116
202206 0.181 113.600 0.189
202209 0.384 116.400 0.391
202212 0.059 115.900 0.060
202303 0.639 117.300 0.645
202306 0.067 116.400 0.068
202309 0.395 117.400 0.398
202312 0.326 116.700 0.331
202403 0.303 118.400 0.303

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Genmab A/S  (STU:GE91) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Genmab A/S's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=27.00/0.53
=50.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Genmab A/S was 914.08. The lowest was 48.40. And the median was 158.63.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Genmab A/S Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (STU:GE91) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (STU:GE91) » Definitions » Cyclically Adjusted FCF per Share
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (STU:GE91) Headlines

No Headlines